Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

We Told You to Buy Furiex: $FURX is Up 132% Today

We usually don’t share our best ideas publicly. In our quarterly newsletter we share 15 ideas and in our monthly newsletters we share 1 or 2 ideas. It isn’t like we make dozens of recommendations every day. In our December newsletter we shared Michael Castor’s best idea at that moment: Furiex Pharma (FURX). You probably don’t know who Michael Castor is. We do. Michael Castor is 2013’s best hedge fund manager. Please read our article to see how Michael Castor has been pulling one rabbit after another from his hat. He recommended 8 stocks for us throughout 2013 and six of those stocks returned more than 100% in under a year. We track a lot of hedge funds and we have never seen anything like this before.

Sio Capital

On January 25th we published the January issue of our monthly newsletter. Here is what Castor said about Furiex in that newsletter:

FURX remains a good pick. There is a change – they earn a royalty on a diabetes drug sold by Takeda. The launch has been slower than I expected. I had initially thought that royalty stream to be worth $30 or so. I now think it is worth about $22. I continue to think the chance of success of eluxadoline is about 65% and that the value of the company with good clinical data is about $75. Mathematically, (65%)*($75) + (35%)*($22) = ~$56, so I like the stock at these levels, but it is high risk and has ~50% downside potential.

He was a little bit lucky but this is what investing is. You make calculated bets where the odds are on your side. If your assessments are accurate you should be able to outperform the market on average.

We said Michael Castor made 8 recommendations in 2013 and six of them at least doubled. His worst performing recommendation is Aratana (PETX). The stock was trading at $15 in September when he recommended it. Today, it is trading at $21, up 40%. Castor thinks the stock may reach $40 in about three years, so this is a long-term play. Check this stock out.

In 2014, Michael Castor recommended one stock. This is also a long-term stock pick which, he thinks, may triple or quadruple in 2-3 years. We already shared this stock with our newsletter subscribers and we will share this name publicly after it doubles. Michael Castor is the next great hedge fund manager; do yourself a favor and start tracking his moves.

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!